Southern Fund's Hong Kong Stock Connect Innovative Drug ETF Southern (159297) rose more than 3% during intraday trading, and Asieris Pharmaceuticals' multiple preclinical studies were selected for the 2026 AACR Annual Meeting

NightAirdropper

2026-03-25 02:24:17

Abstract generation in progress

As of March 24, 2026, 10:02 AM, the Southbound Innovation Drug ETF (159297) surged over 3% at one point, currently up 2.24%. The intraday turnover rate is 5.71%, with a transaction volume of 92.9366 million yuan. It tracks the China Securities Index of Hong Kong Stock Connect Innovation Drugs (987018), which has risen strongly by 1.03%.

In recent news, Yasheng Medicine announced that four of its preclinical research progress projects have been selected for the 2026 American Association for Cancer Research (AACR) Annual Meeting. The relevant data cover three of the company’s ongoing anti-tumor drugs. This marks international recognition of its innovative drug development progress on a prestigious academic platform. The conference will be held from April 17 to April 22, 2026, in San Diego, California, hosted by AACR, one of the most influential cancer research events worldwide.

Institutions point out that during the decade-long innovation transformation period from 2015 to 2025, China’s pharmaceutical industry has basically completed the transition from old to new growth drivers, significantly opening up growth potential. Currently, China’s innovative industry has taken shape, with traditional pharmaceutical companies successfully transforming into innovative drug companies, which are also entering a rapid development phase.

The Southbound Innovation Drug ETF (159297) closely tracks the China Securities Index of Hong Kong Stock Connect Innovation Drugs. The index aims to reflect the operational characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect scope. The top ten weighted stocks are CSPC Pharmaceutical Group, Innovent Biologics, BeiGene, China Biologic Products, Kangfang Biotech, Hansoh Pharmaceutical, Sino Biopharmaceutical, Kelun-BH Biotech, Kangzhe Pharmaceutical, and United Laboratories.

The Southbound Innovation Drug ETF (159297) provides a convenient tool for investing in the Hong Kong innovative drug sector. With a clear industry trend, long-term investment value is highlighted. Its low management fee of 0.15% per year offers a cost-effective way for investors to allocate core assets in Hong Kong’s innovative drug market.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.